Biologic agents and immunotherapy in rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 24, Issue 3, 1998, Pages 537-565

  Wallis, W J ^a   Furst, D E ^a   Strand, V ^a   Keystone, E ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE RECEPTOR; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BIOTECHNOLOGY; CYTOKINE PRODUCTION; GENE THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031671037     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70025-9     Document Type: Article

References (130)

1. L. Adorini Z.A. Nagy Peptide competition for antigen presentation Immunol Today 11 1990 21
2. S. Akira T. Taga T. Kishimoto Interleukin-6 in biology and medicine Adv Immunol 54 1993 1
3. L. Albert J.E. Enoksen L.E. Mason Recombinant human soluble P-Selectin glycoprotein ligand-1 decreases adjuvant-induced arthritis in Lewis rats Arthritis Rheum 40 suppl 1997 74
4. J.B. Allen H.L. Wong G.L. Costa Suppression of monocyte function and differential regulation of IL-2 and IL-1a by IL-4 contribute to resolution of experimental arthritis J Immunol 151 1993 4344
5. A.C. Bakker L.A.B. Joosten O.J. Arntz Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee Arthritis Rheum 40 1997 893
6. M.L. Barnett J.M. Kremer St.Clair E.W. Treatment of rheumatoid arthritis with oral type II collagen Arthritis Rheum 41 1998 290
7. R.J. Benjamin S. Quin M.P. Wise Mechanism of MoAb-facilitated tolerance induction: A possible role for the CD4 (L3T4) and CD11a (LFA-1) molecule in self/non-self discrimination Eur J Immunol 18 1988 1079
8. N. Bessis M. Boissier P. Ferrara Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13 Eur J Immunol 26 1996 2399
9. C.I. Bindon G. Hole H. Waldmann Importance of antigen specificity for complement-mediated lysis by MoAbs Eur J Immunol 18 1988 1507
10. J. Bondeson K.A. Browne F.M. Brennan Adenoviral transfer of the IkB gene inhibits the induction of proinflammatory cytokines Arthritis Rheum 40 suppl 1997 322
11. F.C. Breedveld CD4 monoclonal antibody therapy in rheumatoid arthritis Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for the Treatment of Autoimmune Diseases 1997 Marcel Dekker New York 55
12. F.M. Brennan D. Chantry A.M. Jackson Cytokine production in culture by cells isolated from the synovial membrane J Autoimmun 2 suppl 1989 177
13. Bresnihan B. on behalf of the collaborating investigators Treatment with recombinant human interleukin-1 receptor antagonist (rHU-1ra) in rheumatoid arthritis: Results of a randomized, double-blind, placebo-controlled, multicenter trial Arthritis Rheum 9 suppl 1993 73.6
14. M. Bruggeman G.O. Williams C.I. Bindon Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies J Exp Med 166 1987 1315
15. A. Bucht J.R. Oksenberg S. Linblod Characterization of T-cell receptor β-repertoire in synovial tissue from different temporal phases of RA Scand J Immunol 35 1992 159
16. D.M. Butler R.N. Maini M. Feldman Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNF-alpha antibody with the interleukin-1 receptor antagonist Eur Cytokine Netw 6 1995 225
17. G.W. Cannon R.D. Emkey A. Denes Prospective 5-year follow-up of recombinant interferon in rheumatoid arthritis J Rheumatol 20 1993 1867
18. I.R. Cohen J. Holoshitz van Eden W. T-lymphocyte clones illuminate pathogenesis and effect therapy of experimental arthritis Arthritis Rheum 28 1985 841
19. G. Cunnane A. Madigan O. Fitzgeral Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) may reduce synovial infiltration in RA Arthritis Rheum 39 suppl 1996 245
20. J.J. Cush Anti-CD5/Ricin A chain immunoconjugate therapy in rheumatoid arthritis Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for Treatment of Autoimmune Diseases 1997 Marcel Dekker New York 11
21. P. Das D.S. Bradley M.M. Griffiths An HLA-DRB1*0402 derived peptide (65-79) prevents the onset of collagen-induced arthritis in HLA DQ8 transgenic mice Arthritis Rheum 40 suppl 1997 72
22. B.W. Deleuran C.Q. Chu M. Field Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implication for local actions of tumor necrosis factor alpha Arthritis Rheum 35 1992 1170
23. C. Dinarello Biologic basis for interleukin-1 in disease Blood 87 1996 2095
24. P.J. Doherty Gene therapy and arthritis J Rheumatol 22 1995 1220
25. B.E. Drevlow R. Lovis M.A. Haag Recombinant human interleukin-1 receptor, type I (rhuIL-1RI) in the treatment of patients with active rheumatoid arthritis Arthritis Rheum 39 1995 257
26. F.H. Durie R.A. Fava T.M. Foy Prevention of collagen-induced arthritis with an antibody gp39, the ligand for CD40 Science 261 1993 1328
27. D. Elewaut F. DeKeyser VanDen Bosch F. Clonal analysis of T-cell liver expanded from rheumatoid synovium and subcutaneous nodules: Broadening of the clonal spectrum in rheumatoid synovium in relation to disease duration Arthritis Rheum 40 suppl 1997 196
28. M.J. Elliot R.N. Maini M. Feldmann Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α Arthritis Rheum 21 1993 318
29. M.J. Elliot R.N. Maini M. Feldmann Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor A (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1104
30. W.V. Epstein Expection bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience Arthritis Rheum 39 1996 1773
31. C. Evans P.D. Robbins Prospects for treating arthritis by gene therapy J Rheumatol 21 1994 779
32. J. Evans D. Yocum M. Maricic Results of an open-label, dose-ranging, safety and pharmacokinetic trial of the humanized tumor necrosis factor antibody (HTA), bay 103356, in patients with active rheumatoid arthritis (RA) Arthritis Rheum 40 suppl 1997 224
33. H.G. Fassbender M. Seibel T. Hebert Pathways of destruction in metacarpal and metatarsal joints of patients with rheumatoid arthritis Scand J Rheumatol 21 1992 10
34. G.S. Firestein F. Escheverri M. Yeo Somatic mutations in the P53 tumor suppressor gene in rheumatoid arthritis (RA) synovium J Clin Invest 96 1985 1631
35. K. Fujisawa H. Asahara K. Okamoto Therapeutic effect of the anti-FAS antibody on arthritis in HTLV-1 tax transgenic mice J Clin Invest 98 1996 271
36. D.E. Furst M. Weisman H.E. Paulus Neutralization of TNF by Lenercept (TNF R55-IgG1, Ro 45-2081) in patients with RA treated for 3 months: Results of a US phase II trial Arthritis Rheum 39 suppl 1996 243
37. S.C. Ghivizzani R. Kang T. Muzzonigro Gene therapy for arthritis: Treatment of the first three patients Arthritis Rheum 40 1997 223
38. D. Goldberg P. Morel L. Chatteroud Immunological effect of high dose administration of anti-CD4 antibody in RA patients J Autoimmun 2 1989 627
39. 9 mice leads to a TH 2-type cytokine response Arthritis Rheum 40 suppl 1997 54
40. D.A. Hafler H.L. Weiner Oral tolerance for the treatment of autoimmune disease Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for the Treatment of Autoimmune Diseases 1997 Marcel Dekker New York 201
41. J.T. Han L.D. Butler P.E. Reidi The progression of inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents that inhibit T-cell activities Eur J Immunol 18 1988 881
42. C. Haworth F.M. Brennan D. Chantry Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis regulation by tumor necrosis-alpha Eur J Immunol 21 1991 2575
43. R.A. Heller M. Kronke TNF receptor-mediated signalling pathways J Cell Biol 126 1994 5
44. P.S. Hench E.C. Kendall C.H. Slocumb The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocortisone:compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Preliminary Report Proc Staff Meet Mayo Clin 24 1949 181
45. C. Herzog C. Walker W. Muller Anti-CD4 antibody treatment of patients with RA:I. Effect on clinical course and circulating T cells J Autoimmun 2 1989 627
46. R. Hohlfeld Biotechnological agents for the immunotherapy of multiple sclerosis Brain 120 1997 865
47. G. Horneff G.R. Burnmester F. Emmrich Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody Arthritis Rheum 34 1991 129
48. M.D. Howell J.P. Dively K.A. Lundeen Limited T-cell receptor β-chain heterogeneity among interleukin-2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis Proc Natl Acad Sci U S A 88 1991 10921
49. J.D. Isaacs R.A. Watts B.L. Hazleman Humanized monoclonal antibody therapy for rheumatoid arthritis Lancet 340 1992 748
50. H.E. Jasin E. Lightfoot L.S. Davis Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules Arthritis Rheum 35 1992 541
51. L.A.B. Joosten E. Lubberts P. Durez Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: Protective effect of interleukin-4 and interleukin-10 in treatment of cartilage destruction Arthritis Rheum 40 1997 249
52. C. Jorgenson F. Apparailly F. Canovas Chondroprotective effect of the gene of IL-10 transduced in vivo to human rheumatoid synovium engrafted to SCID mice Arthritis Rheum 40 suppl 1997 50
53. A.F. Kavanaugh L.S. Davis L.A. Nichols Treatment of refractory rheumatoid arthritis with a monoclonal antibody to inter-cellular adhesion molecule 1 Arthritis Rheum 37 1994 992
54. A.F. Kavanaugh H. Schulze-Koops L.S. Davis Repeat treatment of rheumatoid arthritis patients with a murine anti-intracellular adhesion molecule-1 monoclonal antibody Arthritis Rheum 40 1997 849
55. J. Keffer L. Probert H. Cazlaris Transgenic mice expressing human tumour factor: A predictive genetic model of arthritis EMBO J 10 1991 4025
56. B.W. Kirkenhaus F. Thien B.K. Pelton Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis J Rheumatol 19 1992 1340
57. P. Larsson R. Holindahl L. Kloreskog In vitro treatment with anti-CD8 and anti-CD5 MoAbs alters induced tolerance in adjuvant-induced arthritis J Cell Biol 40 1989 49
58. N.G. Levitt M.F. Fernandez P.H. Wooley Pristane-induced arthritis in mice: IV immunotherapy with monoclonal antibodies against lymphocyte subsets J Rheumatol 19 1992 1342
59. R.N. Maini H.E. Paulus F.C. Breedveld rHUIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study Arthritis Rheum 40 suppl 1997 158
60. S. Makarov A. Miagkov D. Kovalenko NF-kB controls apoptosis in arthritis Arthritis Rheum 40 suppl 1997 322
61. E.L. Matteson D. Yocum St.Clair E.W. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection Arthritis Rheum 38 1995 1187
62. M. Mihara M. Kotoh Y. Oda Anti-IL-6 receptor antibody suppresses the onset of collagen arthritis in monkeys Arthritis Rheum 40 suppl 1997 133
63. Miltenburg A.M.M. van Laar J.M. de Kuiper R. Interleukin-6 activity in paired samples of synovial fluid. Correlation of synovial fluid interleukin-6 levels with clinical and laboratory parameters of inflammation Br J Rheumatol 30 1991 186
64. P. Miossec P. Chomarat J. Dechanet Bypassing the antigen to control rheumatoid arthritis Immunol Today 17 1996 170
65. Miossec P. van den Berg W. TH1/TH2 cytokine balance in arthritis Arthritis Rheum 40 1997 2105
66. C.F. Mojcik E.M. Shevach Adhesion molecules: A rheumatologic perspective Arthritis Rheum 40 1997 991
67. T. Moreau A. Coles M. Wing Transiant increase in symptoms associated with cytokine release in patients with multiple sclerosis Brain 119 1996 225
68. L.W. Moreland S.W. Baumgartner M.H. Schiff Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p 75)-Fc fusion protein N Engl J Med 337 1997 141
69. L.W. Moreland R.P. Bucy R.W. Knowles Treating rheumatoid arthritis with a non-depleting anti-CD4 monoclonal antibody Arthritis Rheum 38 suppl 1995 186
70. Moreland L.W. Heck I.W. Jr W.J. Koopman Vβ17 T-cell receptor peptide vaccination in rheumatoid arthritis J Rheumatol 23 1996 1353
71. L.W. Moreland W.J. Koopman Chimeric anti-CD4 antibody as a potential therapeutic agent for rheumatoid arthritis Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for the Treatment of Autoimmune Diseases 1997 Marcel Dekker New York 41
72. L.W. Moreland W.J. Koopman T. Adamson Results of phase II rheumatoid arthritis clinical trial using T-cell receptor peptides Arthritis Rheum 40 suppl 1997 223
73. L.W. Moreland G.R. Margolies Heck I.W. Jr Soluble tumor necrosis factor receptor (sTNFR): Results of a phase I dose-escalation study in patients with rheumatoid arthritis Arthritis Rheum 37 suppl 1994 295
74. L.W. Moreland P.D. Pratt M. Mayes Double-blind placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate Arthritis Rheum 38 1995 1568
75. L.W. Moreland K.L. Sewell D.E. Trentham Interleukin-2 diphtheria fusion protein (DAB486-IL-2) in refractory rheumatoid arthritis Arthritis Rheum 38 1995 1177
76. T. Nakajima H. Hono T. Hasunuma Apoptosis and functional fas antigen in RA synoviocytes Arthritis Rheum 38 1995 485
77. N.H. Nam D. Reda S. Boujouko Recombinant human chimeric TNF receptor (TNFR:Fc): Safety and pharmacokinetics in humans [abstract] Clin Res 41 1993 249A
78. N. Nishioka H. Tomoka T. Kato Apoptosis in RA Arthritis Rheum 41 1998 1 9
79. G. Nuki B. Rozman K. Pavelka Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis Arthritis Rheum 40 suppl 1997 224
80. M. Odeh Short analytical review. New insights into the pathogenesis and treatment of rheumatoid arthritis Clin Immunol Immunopathol 83 1997 103
81. S. Ohshima Y. Saeki T. Mima Tumor necrosis factor α (TNFα) interferes with FAS mediated apoptotic cell death on RA synovial cells: Possible mechanism for synovial hyperplasia and clinical benefit of anti-TNFα therapy in rheumatoid arthritis Arthritis Rheum 40 suppl 1997 335
82. N.J. Olsen R.H. Brooks J.J. Cush A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma Investigator Group Arthritis Rheum 39 1996 1102
83. N. Oppenheimer-Marks P.E. Lipsky B. Henderson Leukocyte adhesion and leukocyte traffic in rheumatoid arthritis Henderson B. Edwards J.C. Pettipler L.R. Mechanisms and Models in Rheumatoid Arthritis 1995 Academic Press London 221
84. W.M. Paleolog M. Hunt M.J. Elliott Deactivation of vascular endothelium by monoclonal anti-TNFα antibody in rheumatoid arthritis Arthritis Rheum 39 1996 1082
85. G.S. Panayi E.H.S. Choy D.A. Connonny Humanized non-depleting anti-CD4 monoclonal antibody treatment: Suppression of disease activity and acute phase response [abstract] Arthritis Rheum 39 suppl 1996 244
86. G.S. Panayi J.S. Lanchbury G.H. Kingsley Deactivation of vascular endothelium by monoclonal anti-TNFα antibody in rheumatoid arthritis Arthritis Rheum 35 1992 729
87. S. Persson A. Mikulowska S. Narula Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats Scand J Immunol 44 1996 606
88. W. Pratt L. Heck L.W. Moreland Safety and immunogenicity of a single intramuscular injection of a synthetic HLA-DR4/1 peptide vaccine with alum adjuvant in rheumatoid arthritis patients Arthritis Rheum 38 suppl 1995 281
89. F. Quagliata E.J. Schenkelaars S. Ferrone Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4 Isr J Med Sci 29 1993 154
90. E.C.C. Rankin E.H.S. Choy D. Kassimos The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody CDP571 in rheumatoid arthritis Br J Rheumatol 34 1995 334
91. H. Reiser M.J. Stadecker Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases N Engl J Med 335 1996 1369
92. C. Reiter B. Kakavand E.P. Rieber Treatment of rheumatoid arthritis with monoconal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration Arthritis Rheum 34 1991 525
93. E. Robey J.P. Allison T-cell activation: Integration of signals from the antigen receptor and co-stimulatory molecules Immunol Today 16 1995 306
94. P. Roux-Lombard L. Punzi F. Hasler Soluble tumor necrosis receptors in human inflammatory synovial fluids Arthritis Rheum 36 1993 485
95. O. Sander R. Rau Long-term observation of 80 patients with TNFα receptor fusion protein (TNFR55-IGG1, RO 45-2081) Arthritis Rheum 40 suppl 1997 224
96. O. Sander R. Rau van Riel P. Neutralization of TNF by Lenercept (TNF R55-IgG1, Ro45-2081) in patients with RA treated for 3 months: Results of a European phase II trial Arthritis Rheum 39 suppl 1996 242
97. H. Schultze-Koops J.S. Davis P. Haverty Reduction of TH1 cell activity in patients with rheumatoid arthritis after treatment with non-depleting monoclonal antibody to CD-4 Arthritis Rheum 40 suppl 1997 191
98. M.A. Schwartz M.D. Schabler M.H. Ginsberg Models of T cell anergy: Is there a common molecular mechanism? Comment on: J Exp Med 184:19–29, 1996 J Exp Med 184 1996 1
99. K.L. Sewell K.P. Parker T.G. Woodworth DAB486IL-2 fusion toxin in refractory RA Arthritis Rheum 26 1993 1223
100. J. Sieper S. Kary U. Eggens Treatment of rheumatoid arthritis with oral collagen type II: Results of a double-blind placebo-controlled randomized trial Arthritis Rheum 38 suppl 1995 312
101. A.M. Solinger T. Alemseged J.A. Lipani The therapeutic potential of a primatized TM, non-depleting anti-CD4 (IDEC-CE9.1) monoclonal antibody in rheumatoid arthritis Hamis W.J. Adair J.R. Antibody Therapeutics 1997 CRC Press Boca Raton 341
102. Tak P.P. van der Lubbe P.A. A. Cauli Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in rheumatoid arthritis Arthritis Rheum 38 1995 1457
103. T. Tomita E. Takeuchi N. Tomita In vivo transfection of NF-kB decoy reduced severity of rat collagen-induced arthritis as a gene therapy Arthritis Rheum 40 suppl 1997 220
104. K.J. Tracey A. Cerami TNF, other cytokines and disease Annu Rev Cell Biol 9 1993 317
105. D.E. Trentham R.A. Dynesius-Trentham E.J. Orav Effects of oral administration of type II collagen on rheumatoid arthritis Science 261 1993 1669
106. van der Lubbe P.A. B.A.C. Dijkmans H.M. Markusse A randomised double-blind placebo controlled trial of CD4 monoclonal antibody therapy in early rheumatoid arthritis Arthritis Rheum 38 1995 1097
107. A.A. Vanderbark G. Hashim H. Offner Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis Nature 341 1989 541
108. E.M. Veys C.J. Menkes P. Emery A randomized double-blind study comparing L4 treatment with recombinant interferon gamma vs. placebo in the treatment of RA Arthritis Rheum 40 1997 62
109. I. Watt M. Cobby Amgen rhIL-1ra clinical research project team. Recombinant human IL-1 receptor antagonist (rhIL-1ra) reduces the rate of joint erosion in RA Arthritis Rheum 39 suppl 1996 123
110. L.M.C. Webb M.J. Walmsley M. Feldmann Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2 Eur J Immunol 26 1996 2320
111. M. Weinblatt J.S. Coblyn A. Maier Continued lymphocyte suppression following single dose mAb therapy with CAMPATH-1H:A 20 month follow-up Arthritis Rheum 39 suppl 1996 245
112. M. Weinblatt P.J. Maddison K.J. Bulpitt CAMPATH-1H, a humanized monoclonal antibody, in refractory RA Arthritis Rheum 38 1995 1589
113. M. Weinblatt L.W. Moreland M.H. Schiff Long-term and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p 75 FC fusion protein (TNFR-FC Enbrel) Arthritis Rheum 40 suppl 1997 126
114. H.L. Weiner A. Friedman A. Miller Oral tolerance: Immunological mechanisms and treatment of animal and human organ specific autoimmune diseases by oral administration of autoantigens Annu Rev Immunol 12 1994 809
115. D. Wendling E. Racadot J. Wigdenes Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody J Rheumatol 20 1992 289
116. D. Wendling E. Racadot J. Wigdenes The French Investigator's Group: Randomized double-blind, placebo-controlled multicentre trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis Arthritis Rheum 39 suppl 9 1996 245
117. D. Wendling J. Wigdenes E. Racadot Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis J Rheumatol 18 1991 325
118. J.D. Whalen C.A. Carlos P.D. Robbins Periarticular gene therapy with viral IL-10 can prevent collagen-induced arthritis in mice Arthritis Rheum 40 suppl 1997 158
119. R.O. Williams M. Feldmann R.N. Maini Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc Natl Acad Sci U S A 89 1992 9754
120. P.H. Wooley J. Dutcher M.B. Widmer Influence of a recombinant human soluble tumor necrosis factor receptor antagonist protein on type II collagen-induced arthritis in mice J Immunol 11 1993 6602
121. S. Yashino L.G. Cleland G. Mayrhofer Treatment of CIA in rats with a MoAb against the alpha/beta T-cell receptor Arthritis Rheum 34 1991 1039
122. D. Yocum A.M. Solinger J.A. Lipani The use of CE9.1, a primatized monoclonal anti-CD4, in the treatment of rheumatoid arthritis Strand V. Scott D.L. Simon L.S. Novel Therapeutic Agents for the Treatment of Autoimmune Diseases 1997 Marcel Dekker New York 65
123. M. Yuhe L.E. Duwel S. Thornton Viral interleukin-10 gene therapy inhibits collagen-induced arthritis in mice Arthritis Rheum 40 suppl 1997 158
124. G. Zagon J.R. Tumang Y. Li Increased frequency of Vβ17-positive T cells in rheumatoid arthritis Arthritis Rheum 37 1994 1431
125. H. Zhang Y. Yang J.L. Horton Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer Arthritis Rheum 49 suppl 1997 294
126. Z.Y. Zhang C.S.Y. Lee O. Lider Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen J Immunol 145 1990 2489
127. N.J. Zvaifler Pathogenic mechanisms as targets for therapy in rheumatoid arthritis van de Putte L.B.A. Furst D.E. Williams H.J. van Reil P.L.C.M. Therapy of Systemic Disorders 1998 Marcel Dekker New York 1
128. α by intravenous infusion of a chimeric monoclonal TNFα antibody in patients with rheumatoid arthritis: Short-term cellular and molecular effects J Immunol 156 1996 1646
129. α MoAb treatment of rheumatoid arthritis patients with active disease on methotrexate: Results of a double-blind placebo controlled multicenter trial Arthritis Rheum 39 suppl 1996 123
130. A.F. Kavanaugh J.J. Cush St.Clair E.W. Treatment of rheumatoid arthritis patients with active disease on methotrexate: Results of open label repeated dose administration following a single dose double-blind placebo controlled trial Arthritis Rheum 39 suppl 1996 244